RxDoctor Payments Data

Danielle Duret, MD

Internal Medicine · Bronx, NYNPI 1942393152

Payments from drug & device makers

$1,342in general payments, 2019–2025

Across 32 payments — averaging $41.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$768
  • GSK$135
  • Esperion Therapeutics, Inc.$125
  • Amgen$125
  • Viiv Healthcare Company$123
  • Lundbeck LLC$42
  • plus $25 from 1 others

What the payments were for

  • Food & beverage$1,342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,342 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$17,568
Medicare patients
48
Services billed
197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide230$277,902
JanuviaSitagliptin Phosphate209$217,242
JardianceEmpagliflozin161$142,785
EliquisApixaban149$135,315
RestasisCyclosporine157$116,468
TrulicityDulaglutide62$74,988
BiktarvyBictegrav/Emtricit/Tenofov Ala12$43,312
XiidraLifitegrast62$42,159
VascepaIcosapent Ethyl88$39,362
FarxigaDapagliflozin Propanediol32$37,816
Albuterol Sulfate HfaAlbuterol Sulfate854$34,506
Breo ElliptaFluticasone/Vilanterol76$33,393
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog85$31,516
PrezcobixDarunavir/Cobicistat12$30,854
JanumetSitagliptin Phos/Metformin Hcl38$28,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$768$292,265242 claims
GSKBreo Ellipta, Incruse Ellipta, Trelegy Ellipta, Arnuity Ellipta, Anoro Ellipta$135$74,307179 claims
AmgenProlia$125$24,78415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →